Clover Health (CLOV) shares surged 13.99% on Wednesday, finishing at $4.89 and reaching an intraday peak of $5.14, following the company’s announcement of a significant Medicare star rating improvement from the Centers for Medicare & Medicaid Services.
Clover Health Investments, Corp., CLOV
The healthcare technology company extended its winning streak to three consecutive sessions while establishing a new 52-week high.
The driving force: CMS revised CLOV’s 2026 Medicare star rating upward to 4.5 Stars from the previous 3.5 Stars, following a court decision in the company’s favor.
The revised rating covers Contract H5141, representing Clover’s PPO Medicare Advantage offering, which encompasses over 97% of the company’s membership base.
This updated rating will have direct implications for 2027 reimbursement levels, including qualification for CMS quality bonus payments — a tangible financial benefit rather than merely a reputational win.
The rating adjustment resulted from legal action initiated by Clover. The company filed suit against CMS and the U.S. Department of Health and Human Services, contending that the agency employed “improper” quality assessment criteria and calculation methods when determining the initial 3.5-star rating.
Clover maintained that the appropriate rating should have been 4.0 Stars, asserting that the lower rating would have resulted in significant financial losses through reduced quality bonuses and government payments, damaged its market position, and hindered expansion prospects.
On May 29, 2026, the U.S. District Court for the Southern District of Georgia ruled in Clover’s favor, invalidating the original rating and mandating that CMS perform a new calculation.
CMS informed Clover of the revised 4.5-star rating on June 9 — exceeding even the company’s original 4.0-star request.
The star rating announcement builds upon increasingly positive operating results.
Clover delivered its inaugural positive GAAP net income during Q1 2026, accompanied by substantial year-over-year revenue growth.
Canaccord analyst Richard Close recently increased his price target on CLOV shares while maintaining a Buy rating. Close pointed to favorable trends in managed care that are supporting digital health providers.
This fundamental improvement provided additional support for Wednesday’s strong stock performance.
The rally was particularly notable considering the challenging market backdrop on the day.
The May 2026 CPI data, released Wednesday morning, revealed headline inflation accelerating to 4.2% year-over-year — the highest reading since 2023 — fueled by surging energy prices linked to geopolitical developments.
The S&P 500, Dow Jones, and Nasdaq all posted declines during the trading session in response.
CLOV defied the broader downturn convincingly, propelled by a company-specific legal victory carrying immediate financial implications.
CMS formally notified Clover of the enhanced 4.5-star rating on June 9, 2026.
The post Clover Health (CLOV) Stock Jumps 14% on Medicare Star Rating Boost to 4.5 appeared first on Blockonomi.
